{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:42:28Z","timestamp":1790854948973,"version":"4.1.0"},"reference-count":122,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5611,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.nurt.2008.01.008","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T09:42:40Z","timestamp":1207129360000},"page":"181-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Symptomatic Treatment of Huntington Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Octavian R.","family":"Adam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2008.01.008_bib1","series-title":"Huntington disease","first-page":"369","article-title":"Principles and practice of movement Disorders","author":"Fahn","year":"2007"},{"key":"10.1016\/j.nurt.2008.01.008_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/mds.21195","article-title":"Autopsy-proven Huntington\u2019s disease with 29 trinucleotide repeats","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib3","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.nurt.2008.01.008_bib4","series-title":"Huntington\u2019s disease","first-page":"2869","article-title":"Neurological therapeutics: principles and practice","author":"Jankovic","year":"2006"},{"key":"10.1016\/j.nurt.2008.01.008_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington\u2019s Disease Rating Scale: reliability and consistency","volume":"11","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib6","first-page":"534","article-title":"Abnormal involuntary movement scale","author":"Guy","year":"1976"},{"key":"10.1016\/j.nurt.2008.01.008_bib7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14656566.8.2.141","article-title":"A systematic review of the treatment studies in Huntington\u2019s disease since 1990","volume":"8","author":"Bonelli","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nurt.2008.01.008_bib8","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1212\/WNL.54.2.452","article-title":"Rate of functional decline in Huntington\u2019s disease","volume":"54","author":"Marder","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/mds.870100213","article-title":"Functional decline in Huntington\u2019s disease","volume":"10","author":"Feigin","year":"1995","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2008.01.008_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1586\/14737175.6.1.7","article-title":"Tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"6","author":"Kenney","year":"2006","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.nurt.2008.01.008_bib12","first-page":"207","article-title":"Treatment of Huntington\u2019s chorea with tetrabenazine (Nitoman)","volume":"125","author":"M\u00f8ller-Christensen","year":"1963","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.nurt.2008.01.008_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/bmj.2.5654.422","article-title":"Effect of tetrabenazine on extrapyramidal movement disorders","volume":"2","author":"Dalby","year":"1969","journal-title":"Br Med J"},{"key":"10.1016\/j.nurt.2008.01.008_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.wnf.0000136892.24629.96","article-title":"Tetrabenazine treatment in movement disorders","volume":"27","author":"Paleacu","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00002826-200211000-00003","article-title":"Tetrabenazine treatment for Huntington\u2019s disease-associated chorea","volume":"25","author":"Ondo","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","article-title":"Tetrabenazine therapy of dystonia, chorea, tics and other dyskinesias","volume":"38","author":"Jankovic","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind cross-over study","volume":"11","author":"Jankovic","year":"1982","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","article-title":"Tetrabenazine and movement disorders","volume":"31","author":"Asher","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0014-2999(84)90562-4","article-title":"Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants","volume":"102","author":"Pettibone","year":"1984","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib20","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1476-5381.1977.tb08425.x","article-title":"The mode of action of tetrabenazine on peripheral noradrenergic nerves","volume":"61","author":"Tomlinson","year":"1977","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mds.21161","article-title":"Short-term effects of tetrabenazine on chorea associated with Huntington\u2019s disease","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/WNF.0b013e3180ca77ea","article-title":"A study of chorea after tetrabenazine withdrawal in patients with Huntington\u2019s disease","author":"Frank","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib24","first-page":"282","article-title":"Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements","volume":"4","author":"Gim\u00e9nez-Rold\u00e1n","year":"1989","journal-title":"Neurologia"},{"key":"10.1016\/j.nurt.2008.01.008_bib25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.WNF.0000228369.25593.35","article-title":"Is history of depression a contraindication to treatment with tetrabenazine?","volume":"29","author":"Kenney","year":"2006","journal-title":"Clin Neuropharmacol"},{"issue":"7854","key":"10.1016\/j.nurt.2008.01.008_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(74)93181-X","article-title":"Treatment of Huntington\u2019s chorea with tetrabenazine","volume":"1","author":"Snaith","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.nurt.2008.01.008_bib27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002826-199202000-00009","article-title":"Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington disease","volume":"15","author":"Mateo","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.870110118","article-title":"Tetrabenazine as a cause of neuroleptic malignant syndrome","volume":"11","author":"Ossemann","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/00048677509159834","article-title":"A double blind trial of lithium carbonate and haloperidol in Huntington\u2019s chorea","volume":"9","author":"Leonard","year":"1975","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib30","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1212\/WNL.35.10.1450","article-title":"The gait abnormality of Huntington\u2019s disease","volume":"35","author":"Koller","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib31","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","article-title":"A double blind trial of sulpiride in Huntington\u2019s disease and tardive dyskinesia","volume":"47","author":"Quinn","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1185\/03007998409109601","article-title":"Tiapride versus placebo: a double-blind comparative study in the management of Huntington\u2019s chorea","volume":"9","author":"Deroover","year":"1984","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.nurt.2008.01.008_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1600-0404.1982.tb03060.x","article-title":"Tiapride in the treatment of Huntington\u2019s chorea","volume":"65","author":"Roos","year":"1982","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nurt.2008.01.008_bib34","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington\u2019s disease: an evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nurt.2008.01.008_bib35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"Modern antipsychotic drugs: a critical overview","volume":"172","author":"Gardner","year":"2005","journal-title":"CMAJ"},{"key":"10.1016\/j.nurt.2008.01.008_bib36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/jnnp.63.1.35","article-title":"Clozapine versus placebo in Huntington\u2019s disease: a double blind randomised comparative study","volume":"63","author":"van Vugt","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/ajp.136.3.317","article-title":"The trial use of clozapine for abnormal involuntary movement disorders","volume":"136","author":"Caine","year":"1979","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib38","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1212\/WNL.44.5.821","article-title":"Clozapine in Huntington\u2019s chorea","volume":"44","author":"Bonuccelli","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1212\/WNL.41.1.156","article-title":"Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington\u2019s chorea","volume":"41","author":"Sajatovic","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib40","first-page":"169","article-title":"Efficacy of clozapine in the course of Huntington chorea: apropos of a clinical case","volume":"27","author":"Vallette","year":"2001","journal-title":"Encephale"},{"key":"10.1016\/j.nurt.2008.01.008_bib41","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","article-title":"Olanzapine for Huntington disease: an open label study","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","article-title":"Olanzapine in Huntington\u2019s disease","volume":"105","author":"Paleacu","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nurt.2008.01.008_bib43","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib44","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1590\/S0004-282X2004000600030","article-title":"Functional and motor response to low dose olanzapine in Huntington\u2019s disease: case report","volume":"62","author":"Laks","year":"2004","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.nurt.2008.01.008_bib45","first-page":"524","article-title":"Olanzapine improves chorea in patients with Huntington\u2019s disease","volume":"35","author":"Jim\u00e9nez-Jim\u00e9nez","year":"2002","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00004850-200203000-00009","article-title":"High-dose olanzapine in Huntington\u2019s disease","volume":"17","author":"Bonelli","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib47","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004714-200104000-00023","article-title":"Olanzapine and Huntington\u2019s disease","volume":"21","author":"Bogelman","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib48","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM200009283431316","article-title":"Improvement of Huntington\u2019s disease with olanzapine and valproate","volume":"343","author":"Grove","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nurt.2008.01.008_bib49","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jnnp.67.1.123","article-title":"The use of olanzapine for movement disorder in Huntington\u2019s disease: a first case report","volume":"67","author":"Dipple","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib50","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1590\/S0004-282X1999000500021","article-title":"Brain SPECT imaging in Huntington\u2019s disease before and after therapy with olanzapine: case report","volume":"57","author":"Etchebehere","year":"1999","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.nurt.2008.01.008_bib51","first-page":"1353","article-title":"Clinical experience with risperidone and memantine in the treatment of Huntington\u2019s disease","volume":"98","author":"Cankurtaran","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.nurt.2008.01.008_bib52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1468-1331.2002.0354e.x","article-title":"Risperidone in chorea and psychosis of Huntington\u2019s disease","volume":"9","author":"Erdemoglu","year":"2002","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib53","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/00004714-199902000-00020","article-title":"Effectiveness of risperidone in Huntington chorea patients","volume":"19","author":"Dallocchio","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib54","first-page":"347","article-title":"Use of risperidone in psychosis associated with Huntington\u2019s disease","volume":"6","author":"Madhusoodanan","year":"1998","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/10401239809148945","article-title":"Psychiatric and neuropsychological abnormalities in Huntington\u2019s disease: a case study","volume":"10","author":"Madhusoodanan","year":"1998","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib56","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00004714-199704000-00023","article-title":"Risperidone in treatment of choreoathetosis of Huntington\u2019s disease","volume":"17","author":"Parsa","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","article-title":"Quetiapine in the treatment of behavioral disturbance in patients with Huntington\u2019s disease","volume":"47","author":"Alpay","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1016\/j.nurt.2008.01.008_bib58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/070674370404900617","article-title":"Quetiapine in the management of psychosis secondary to Huntington\u2019s disease: a case report","volume":"49","author":"Seitz","year":"2004","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib59","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s00415-002-0741-1","article-title":"Quetiapine in Huntington\u2019s disease: a first case report","volume":"249","author":"Bonelli","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881103174009","article-title":"Ziprasidone in Huntington\u2019s disease: the first case reports","volume":"17","author":"Bonelli","year":"2003","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib61","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1212\/WNL.59.5.694","article-title":"Huntington\u2019s disease: a randomized, controlled trial using the NMDA-antagonist amantadine","volume":"59","author":"Verhagen Metman","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib62","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1212\/01.WNL.0000068165.07883.64","article-title":"IV amantadine improves chorea in Huntington\u2019s disease: an acute randomized, controlled study","volume":"60","author":"Lucetti","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib63","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneur.60.7.996","article-title":"A randomized trial of amantadine in Huntington disease","volume":"60","author":"O\u2019Suilleabhain","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib64","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.63.3.597","article-title":"IV amantadine improves chorea in Huntington\u2019s disease: an acute randomized, controlled study","volume":"63","author":"Heckmann","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.870110310","article-title":"A controlled trial of remacemide hydrochloride in Huntington\u2019s disease","volume":"11","author":"Kieburtz","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1212\/WNL.57.3.397","article-title":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","volume":"57","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-7091-0579-5_14","article-title":"The N-methyl-d-aspartate antagonist memantine retards progression of Huntington\u2019s disease","volume":"68","author":"Beister","year":"2004","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.nurt.2008.01.008_bib68","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib69","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","article-title":"Dosage effects of riluzole in Huntington\u2019s disease: a multicenter placebo-controlled study","volume":"61","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib70","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q","article-title":"Riluzole therapy in Huntington\u2019s disease (HD)","volume":"14","author":"Rosas","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib71","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s004150170071","article-title":"Riluzole in Huntington\u2019s disease (HD): an open label study with one year follow up","volume":"248","author":"Seppi","year":"2001","journal-title":"J Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib72","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1212\/01.wnl.0000204193.66919.c0","article-title":"Delayed amnesic syndrome after riluzole autointoxication in Huntington disease","volume":"66","author":"Haaxma","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib73","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1212\/WNL.57.6.1141","article-title":"Intoxication with riluzole in Huntington\u2019s disease","volume":"57","author":"Bodner","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib74","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.53.5.1000","article-title":"Influence of lamotrigine on progression of early Huntington\u2019s disease: a randomized clinical trial","volume":"53","author":"Kremer","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib75","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1001\/archneur.1977.00500170062012","article-title":"Valproate sodium in Huntington chorea","volume":"34","author":"Pearce","year":"1977","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib76","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/ajp.135.3.352","article-title":"Sodium valproate in Huntington\u2019s disease","volume":"135","author":"Symington","year":"1978","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib77","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/mds.870080216","article-title":"Adult onset myoclonic Huntington\u2019s disease","volume":"8","author":"Carella","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib78","first-page":"739","article-title":"Action myoclonus in adult Huntington\u2019s disease","volume":"32","author":"Aoba","year":"1992","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.nurt.2008.01.008_bib79","first-page":"639","article-title":"Cortical reflex myoclonus in adult onset Huntington\u2019s disease","volume":"44","author":"Funakawa","year":"2004","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.nurt.2008.01.008_bib80","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/mds.870090609","article-title":"Cortical myoclonus in Huntington\u2019s disease","volume":"9","author":"Thompson","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2377-6-11","article-title":"Dose-dependent improvement of myoclonic hyperkinesia due to valproic acid in eight Huntington\u2019s disease patients: a case series","volume":"6","author":"Saft","year":"2006","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ana.410250308","article-title":"A controlled clinical trial of baclofen as protective therapy in early Huntington\u2019s disease","volume":"25","author":"Shoulson","year":"1989","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib83","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/phrs.2000.0689","article-title":"Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs","volume":"42","author":"Margineanu","year":"2000","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.nurt.2008.01.008_bib84","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/mds.21061","article-title":"Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington\u2019s disease","volume":"21","author":"Zesiewicz","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib85","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.wnf.0000186648.93612.a5","article-title":"Efficacy of levetiracetam in Huntington disease","volume":"28","author":"de Tommaso","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib86","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/01.wnf.0000169732.00690.32","article-title":"Levetiracetam-induced parkinsonism in a Huntington disease patient","volume":"28","author":"Zesiewicz","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib87","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.WNF.0000240946.51994.DF","article-title":"Levetiracetam-induced parkinsonism in a Huntington\u2019s disease patient","volume":"29","author":"Gatto","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib88","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/jnnp.68.2.238","article-title":"Late onset levodopa responsive Huntington\u2019s disease with minimal chorea masquerading as Parkinson\u2019s plus syndrome","volume":"68","author":"Reuter","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib89","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jnnp.65.4.577","article-title":"Levodopa responsive parkinsonism in an adult with Huntington\u2019s disease","volume":"65","author":"Racette","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib90","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200201000-00011","article-title":"Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington\u2019s disease","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib91","first-page":"355","article-title":"Cabergoline in Huntington\u2019s disease: the first case report","volume":"113","author":"Magnet","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.nurt.2008.01.008_bib92","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/01.wnl.0000238106.10423.00","article-title":"Effect of donepezil on motor and cognitive function in Huntington disease","volume":"67","author":"Cubo","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib93","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T","article-title":"Donepezil for Huntington\u2019s disease","volume":"15","author":"Fernandez","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib94","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","article-title":"Effects of rivastigmine on motor and cognitive impairment in Huntington\u2019s disease","volume":"19","author":"de Tommaso","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200401000-00010","article-title":"Treatment of Huntington\u2019s disease with galantamine","volume":"19","author":"Petrikis","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.nurt.2008.01.008_bib96","first-page":"367","article-title":"A case of obsessive symptoms in Huntington\u2019s disease","volume":"31","author":"Royuela Rico","year":"2003","journal-title":"Actas Esp Psiquiatr"},{"key":"10.1016\/j.nurt.2008.01.008_bib97","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.870120319","article-title":"A controlled trial of fluoxetine in nondepressed patients with Huntington\u2019s disease","volume":"12","author":"Como","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.nurt.2008.01.008_bib98","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s002130000575","article-title":"Fluoxetine in the treatment of Huntington disease","volume":"153","author":"De Marchi","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nurt.2008.01.008_bib99","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1055\/s-2003-38093","article-title":"Fluoxetine-induced exacerbation of chorea in Huntington\u2019s disease?","volume":"36","author":"Chari","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10401239609149087","article-title":"l-Deprenyl augmentation of fluoxetine in a patient with Huntington\u2019s disease","volume":"8","author":"Patel","year":"1996","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.nurt.2008.01.008_bib101","first-page":"216","article-title":"Obsessive compulsive disorder in Huntington disease: a case of isolated obsessions successfully treated with sertraline","volume":"15","author":"Patzold","year":"2002","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib102","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1176\/jnp.8.3.338","article-title":"Sertraline in the treatment of severe aggressiveness in Huntington\u2019s disease","volume":"8","author":"Ranen","year":"1996","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.nurt.2008.01.008_bib103","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1345\/aph.1C352","article-title":"Mirtazapine in suicidal Huntington\u2019s disease","volume":"37","author":"Bonelli","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nurt.2008.01.008_bib104","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1176\/jnp.8.2.209","article-title":"ECT in genetically confirmed Huntington\u2019s disease","volume":"8","author":"Lewis","year":"1996","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.nurt.2008.01.008_bib105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ana.20183","article-title":"Bilateral globus pallidus stimulation for Huntington\u2019s disease","volume":"56","author":"Moro","year":"2004","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib106","doi-asserted-by":"crossref","first-page":"E383","DOI":"10.1227\/01.NEU.0000195068.19801.18","article-title":"Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington\u2019s disease: technical case report","volume":"58","author":"Hebb","year":"2006","journal-title":"Neurosurgery"},{"key":"10.1016\/j.nurt.2008.01.008_bib107","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01616412.1995.11740334","article-title":"Fetal striatal homotransplantation for Huntington\u2019s disease: first two case reports","volume":"17","author":"Madrazo","year":"1995","journal-title":"Neurol Res"},{"key":"10.1016\/j.nurt.2008.01.008_bib108","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/096368979700600303","article-title":"Neuropsychological functioning following fetal striatal transplantation in Huntington\u2019s chorea: three case presentations","volume":"6","author":"Philpott","year":"1997","journal-title":"Cell Transplant"},{"key":"10.1016\/j.nurt.2008.01.008_bib109","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1006\/exnr.1997.6685","article-title":"Safety of intrastriatal neurotransplantation for Huntington\u2019s disease patients","volume":"149","author":"Kopyov","year":"1998","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1006\/exnr.1999.7239","article-title":"Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington\u2019s disease","volume":"161","author":"Bachoud-L\u00e9vi","year":"2000","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib111","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","article-title":"Motor and cognitive improvement in patients with Huntington\u2019s disease after neural transplantation","volume":"356","author":"Bachoud-L\u00e9vi","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.nurt.2008.01.008_bib112","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1474-4422(06)70381-7","article-title":"Effect of fetal neural transplants in patients with Huntington\u2019s disease 6 years after surgery: a long-term follow-up study","volume":"5","author":"Bachoud-L\u00e9vi","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib113","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1212\/WNL.58.5.687","article-title":"Bilateral human fetal striatal transplantation in Huntington\u2019s disease","volume":"28","author":"Hauser","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib114","doi-asserted-by":"crossref","first-page":"13877","DOI":"10.1073\/pnas.97.25.13877","article-title":"Transplanted fetal striatum in Huntington\u2019s disease: phenotypic development and lack of pathology","volume":"97","author":"Freeman","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nurt.2008.01.008_bib115","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1212\/01.wnl.0000264504.14301.f5","article-title":"Neural transplantation in Huntington\u2019s disease: long-term grafts in two patients","volume":"68","author":"Keene","year":"2007","journal-title":"Neurology"},{"issue":"Suppl 4","key":"10.1016\/j.nurt.2008.01.008_bib116","first-page":"A80","article-title":"Transplantation of fetal porcine striatal cells in Huntington\u2019s disease: preliminary safety and efficacy results","volume":"50","author":"St. Hillaire","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.01.008_bib117","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","article-title":"Dopaminergic signaling and striatal neurodegeneration in Huntington\u2019s disease","volume":"27","author":"Tang","year":"2007","journal-title":"J Neurosci"},{"key":"10.1016\/j.nurt.2008.01.008_bib118","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuron.2007.11.025","article-title":"Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm","volume":"57","author":"Romero","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.nurt.2008.01.008_bib119","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1042\/CS20050148","article-title":"Pharmaceutical, cellular and genetic therapies for Huntington\u2019s disease","volume":"110","author":"Handley","year":"2006","journal-title":"Clin Sci"},{"key":"10.1016\/j.nurt.2008.01.008_bib120","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/WCO.0b013e3282f12074","article-title":"Huntington\u2019s disease phenocopy syndromes","volume":"20","author":"Wild","year":"2007","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.nurt.2008.01.008_bib121","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/1531-8257(200001)15:1<171::AID-MDS1031>3.0.CO;2-Y","article-title":"Bruxism in Huntington\u2019s disease","volume":"15","author":"Tan","year":"2000","journal-title":"Mov Disord"},{"issue":"7848","key":"10.1016\/j.nurt.2008.01.008_bib122","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(74)92338-1","article-title":"A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea","volume":"1","author":"McLellan","year":"1974","journal-title":"Lancet"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923005603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923005603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2008.01.008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:42:51Z","timestamp":1761806571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923005603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":122,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S1878747923005603"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2008.01.008","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptomatic Treatment of Huntington Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2008.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}